Skip to main content

Table 1 Clinical and molecular genetic summary of the patients

From: PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA)

Case

Age/Sex

Location

Duration

Clinical diagnosis

Symptom

PIK3CA mutation

Other mutations

1

3/M

Knee

3 years

Infantile hemangioma

Pain, increased swelling

p.H1047R

PTEN (c.63dupG)

2

15/M

Thigh muscle

3 months (After Sclerotherapy)

Vascular malformation

Pain, functional restriction, increased swelling,

p.H1047R

TEK (p.W189*), GNA11 (p.E191K), AKT1 (p.R15Q, p.Y229=), PTEN (c.63dupG), HRAS (p.R102W)

3

13/M

Thigh muscle

13 years

Venous malformation

Pain, increased swelling

No mutation

No mutation

4

12/M

Thigh muscle

6 months

Venous malformation or FAVA

Pain, functional restriction

No mutation

TEK (p.R842H)

  1. PIK3CA; phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha, TEK; TEK receptor tyrosine kinase, AKT1; AKT serine/threonine kinase 1, PTEN; phosphatase and tensin homolog, HRAS; HRas proto-oncogene, GTPase